RTTNews | Jul 7, 2021 08:28AM EDT

08:27 Wednesday, July 7, 2021 (RTTNews.com) - ARCA biopharma Inc. (ABIO) said that it has reached a patent assignment agreement with the University Medical Center of Johannes Gutenberg University Mainz, Germany that will provide exclusive world-wide patent rights to the use of rNAPc2 as a potential treatment for COVID-19 and other indications.

rNAPc2 is a recombinant protein therapeutic being developed by ARCA as a potential treatment for COVID-19 and other severe viral infections.

ASPEN-COVID-19 is an on-going Phase 2b clinical trial evaluating rNAPc2 as a potential treatment for patients hospitalized with COVID-19. The U.S. Food and Drug Administration designated the investigation of rNAPc2 as a potential treatment for COVID-19 as a Fast Track development program.

As per the agreement, ARCA also obtains an option to acquire world-wide patent rights to discoveries related to the use of rNAPc2 as a potential therapeutic for auto-immune disorders such as systemic lupus erythematosus, that involve the presence of anti-phospholipid antibodies linked to tissue factor, as well as the option to acquire patent rights for discoveries relating to other therapeutic uses of rNAPc2.

As per the deal, ARCA has potential upfront and milestone obligations that could total about 1.6 million euros and royalty obligations in the low single digit range, if rNAPc2 receives regulatory approval and is commercialized.

Read the original article on RTTNews ( https://www.rttnews.com/3207487/arca-biopharma-gets-patent-rights-to-use-of-rnapc2-as-potential-treatment-for-covid-19.aspx)

For comments and feedback: contact editorial@rttnews.com

Copyright(c) 2021 RTTNews.com All Rights Reserved